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Abstract
Pneumonia is still a global health concern with high mortality rate, mainly among chil-
dren under 5 years and adults over 65 years. In addition to pathogen virulence, immu-
noevasion capacity, and drug resistance ability, risk factors for the patient include aging, 
comorbidities, malnutrition, and all causes affecting the immune system. The extent to 
which environmental disorders affect the respiratory health is established for chronic 
diseases such as asthma, COPD, and cardiovascular diseases, but less is known about the 
underlying mechanisms of their impact on infectious diseases of the respiratory system. 
This chapter aims to recall the epidemiology, diagnosis, and treatment of pneumonia, 
with a focus on the impact of climate change and related risk factors on acute low tract 
respiratory infections.
Keywords: pneumonia, risk factors, climate change
1. Introduction
Pneumonia is a challenging health concern worldwide and more acutely in developing world, 
where healthcare facilities are less available. It is a leading cause of mortality due to infec-
tious agents. Insufficient or inappropriate treatment contributes to the emergence of pathogen 
resistance to antibiotic or increased mortality. A recent report from UNICEF shows 1.4 million 
deaths per year among children attributable to pneumonia and diarrhea [1]. Both killers remain 
major contributors to child mortality worldwide, and could be fueled by climate change and 
related environmental deleterious effects. Pneumonia, a common lower respiratory infection 
accounted for 2.7 million deaths worldwide [2]; being the leading cause in children under 
5 years, adults over 65 years, and immunocompromised subjects [3].
© 2018 The Author(s). Licensee InTech. This chapt r is distributed under the terms of the Creative Comm s
Attribution L cense (http://creativecommons. /licenses/by/3.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
According to the setting of occurrence, pneumonia is characterized as community acquired 
(CAP) or nosocomial, the latter occurring in the hospital after at least 48 h of admission or in 
a patient who has been hospitalized within the last 3–6 months and received antimicrobial 
treatment. Hospital-acquired pneumonia (HAP) includes really hospital acquired, ventilator-
acquired pneumonia (VAP), and healthcare-associated pneumonia (HCAP) with extension to 
disease affecting patients in nursing homes and in dialysis services [4].
CAP represents a disease contracted out of the hospital, in the community. Clinical features 
allow the categorization in classic pneumonia due to bacteria such as Streptococcus pneumoniae, 
Haemophilus influenzae type b, Staphylococcus aureus, and viruses such as respiratory syncy-
tial virus (29%) and influenza virus (17%); most prevalent in children and influenza virus 
most common in adults [4]. Atypical pneumonia results from the infection with intracellular 
bacteria such as Chlamydia and Mycoplasma. Nosocomial pneumonia may affect ventilated 
patients or not and the former group is identified as ventilator-associated pneumonia (VAMP) 
with a greater risk of multidrug resistance and subsequent poor prognosis. Pneumonia in the 
immunosuppressed host is a severe form of the disease, which may affect individual what-
ever the setting, with a poorer prognosis due to the underlying immune status.
Many traditional risk factors have been previously identified including extreme age (children 
under 60 months and adults aged ≥65 years), poverty, and comorbidities. Malnutrition, low 
birth weight, nonexclusive breast-feeding, lack of measles vaccination, outdoor and indoor air 
pollution and crowding, mother’s education, parental smoking, vitamin A and/or zinc defi-
ciencies are thought to influence children susceptibility to infections in developing countries. 
Possible additional risk factors thought to increase the susceptibility to respiratory infections 
and allergic diseases include climate change with the potential of affecting dispersion, tim-
ing, and quality of aeroallergens and the lifecycle of some vectors of diseases, high altitude, 
humidity, and concomitant diseases [5, 6].
This chapter aims to recall the epidemiology, diagnosis, and treatment of pneumonia, with a 
focus on the impact of climate change and related risk factors on acute low tract respiratory 
infection (ALTRI).
2. Climate change and respiratory health
The extent to which outdoor and indoor environments affect the respiratory health is estab-
lished for chronic diseases such as asthma, COPD, and cardiovascular diseases, but less is 
known about the underlying mechanisms of their impact on infectious diseases of the respi-
ratory system. Climate change is claimed to be a great global health concern. The impact of 
industrialization and anarchic urbanization in developing countries contributes to high pro-
duction of greenhouse gases, carbon dioxide (CO
2
), methane (CH
4
), etc., which affect the earth 
temperature. The monthly average temperature is increasing leading to many weather-related 
events such as heat waves, humidity, precipitations, floods, storms, dry conditions, and wild-
fires, which affect differently the environment and human health between temperate and 
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tropical regions [7, 8]. The increased morbidity and mortality due to ALRTI in children and 
adults over 65 years are linked to many risk factors, the additional effect of weather change 
could be powered by the inadaptability of the metabolism of these vulnerable populations to 
heat stress and temperature variations; emphasizing the need for further research addressing 
health effects of climate variations. Strategies addressing climate change are getting more and 
more relevant to give strong support to clean environment. There is a need to better under-
stand the underlying mechanisms of the human, animal, or plant reactions to the changing 
weather to develop appropriate policies with a real impact on the susceptibility of humans 
to deleterious effects of the phenomenon. New technologies are underdeveloped to address 
the physiological responses of human and animal to the environmental-induced stress and 
survival, relaying on DNA/RNA sequencing as reported by Biggar et al. [9]. Stress biology 
research will allow implementation of targeted responses to the health effects of climate 
change. Direct or indirect health effects act through warming temperatures with increase in 
atmospheric ozone, nitrogen oxide, particulate matter (PM), sulfur dioxide, and ultraviolet 
(UV) radiation, resulting in many conditions such as: exacerbations of chronic respiratory dis-
eases (asthma, COPD) and respiratory infections, as well as nonrespiratory diseases including 
heat stress, water-borne diseases, transmittable diseases (malaria), and malnutrition.
Heat waves, floods, wildfires may influence the incidence of respiratory infection through 
the shift in the epidemiology of climate sensitive pathogens. The threat on global health are 
highlighted by many previous studies such as one report from Australia about an increased 
incidence in childhood pneumonia associated with sharp temperature drops from 1 day to 
the next [10], or the outbreak of Hantavirus, which occurred in Panama in 2000, linked to the 
increase in rodent population attributed to a substantial increase in rainfall [11]. A report from 
Japan about aspergillosis among survivors of tsunami in 2011 is one more illustration of the 
link between climate change and respiratory health [12].
Respiratory infection results from inhaled aerosols or hematogenous spread of pathogens. 
Pathogen-related compounds (virulence, concentration, survival) or host related (immunity, 
comorbidities, aging) play a key role in the incidence and severity of the illness. Climate altera-
tions could impact the disease by affecting the vectors or the host immunity [13]. The seasonal-
ity of respiratory infections has been demonstrated for influenza and streptococcal pneumonia 
during winter months in temperate climate [14, 15]. The later study reported a 2% incidence of 
CAP for all overnight hospital admissions, with a significantly higher rate during winter and 
spring, mainly in December and January [15].
Possible explanations of the seasonality seem to be the closer contact as a result of indoor crowd-
ing, lower humidity, induced variations in the human immune responses, indoor air pollution, 
low exposition to sunlight and ultraviolet (UV) radiation, keeping in mind the bactericidal effect 
of the latter [16]. In tropical regions, climate change also affects the pattern and seasonability of 
infections. Temperature, moisture and dehydration, and UV light greatly influence the pathogen 
cycle and survival in the environment and act on the transmission of air-borne aerosols. Dry air 
and wind-driven atmospheric pollutants could act on mucociliary escalator of the respiratory 
mucosa, impairing its defense mechanisms [17], and there is evidence from animal and human 
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studies for the induced weaknesses of the immune system during winter [18]. Immune system 
is also under influence of adrenocortical hormones known to be more expressed during winter 
season than summer, and increased secretion of steroids is associated with immunodeficiency 
[19]. The rainy period is more prone to water-borne diseases such as cholera following floods 
and storms. The changing pattern in vector and pathogen infectivity, the low exposure to sun-
light during rainy seasons, people spending more time indoor in crowded environment, with 
subsequent seasonal variations in vitamin D levels could explain the seasonability of infectious 
diseases. The deficiency in vitamin D linked to the reduced exposure of skin surface to sunlight 
has harmful effect on human immunity [20, 21] and could increase the vulnerability to infec-
tions, mainly in people at extreme ages.
Previous studies have emphasized the harmful role of ambient air pollution and particulate mat-
ter and the heat effect of high temperature on daily mortality [22, 23]. Climate change stands as 
a new health challenge for the increasing morbidity due to respiratory and cardiovascular dis-
eases worldwide. These changes affect physical and biological systems through environmental 
conditions including air and water pollution, water heating, increasing the risk of transmission 
of water-borne pathogens. The impact of air pollution on chronic respiratory diseases such as 
asthma and COPD is well established. The extent to which weather patterns could influence 
respiratory infections is still debatable. Heat, air pollution, change in quantity and quality of 
aeroallergens, and shift in infectious diseases linked to changing ecology of the pathogens have 
been previously reported as strong risk factors affecting respiratory health. Direct health effects 
of climate changes include heat-related illness, exacerbations of chronic cardiorespiratory dis-
eases such as COPD and asthma due to the changing pattern of environmental exposure [24]. 
Previous epidemiological studies suggest the seasonal variability of respiratory infections, but 
the pathobiology of this link is far from being clearly assessed. Cold and dry conditions in tem-
perate regions power the transmission of influenza and respiratory syncytial viruses, while the 
wet conditions of the tropics seem to reduce the aerosol transmission of the influenza virus [25]. 
Studies addressing the link between climate change and pneumonia still need to be conducted 
worldwide, mainly in poor resource countries and also in the most affected by lack of hygiene 
and unpreparedness. Lower respiratory tract infections seem to be more frequent during win-
ter in temperate areas and during rainy season in tropical regions [25, 26]. Studies in Hong 
Kong [27] and China [28], respectively support the impact of the changing weather pattern on 
the magnitude of respiratory infection and the seeking of emergency healthcare. The pattern of 
seasonality on viral respiratory infections has clearly been reported in temperate countries, but 
data from tropical regions are sparse [29]. The vulnerability of children under the tropics could 
be emphasized by poverty-related conditions such as malnutrition and helminth infections as 
well as poor access to healthcare facilities. Chronic helminth infections stimulate the T-cells to 
produce more Th2 type cytokines (IL-3, IL-5, IL-13) than Th-1 profile (IL-2, IFN-gamma). This 
imbalance could be a possible explanation for the increased susceptibility to bacterial infections 
in affected individuals. Lozano et al. have illustrated the negative role of air and water pollu-
tion linked to storms and floods affecting agricultural products. These authors reported an 
increase in pneumonia deaths in children under 5 years due to malnutrition [30]. Malnutrition 
predisposes to immunosuppression through lack of many elements or oligo-elements such as 
zinc and cupper, involved in the functionality of many components of the immune system. 
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Biggar et al. have illustrated the relevance of studying stress biology to characterize human 
responses to environmental challenges [9]; the way we will act to reduce greenhouse gas emis-
sions will really benefit to global health.
How the climate change could impact on the transmission and outcome of infectious dis-
eases needs to be elucidated for appropriate preparedness of the healthy systems around 
the world. Health effects of air pollution are of concern; atmospheric pollutants in gaseous 
(mainly carbon dioxide, methane, nitrous oxide) or particulate forms may affect respiratory 
system according to their physical properties (solubility), their concentration, and the rate 
and depth of the ventilation of the subject. Use of biomass fuel for cooking in many develop-
ing countries increases the risk of exposure to outdoor or indoor pollution. Biologic agents 
such as fungi in indoor air could trigger the respiratory system through direct toxicity, infec-
tion, or induced immune hyperresponsiveness. Smith et al. have described the risk for pneu-
mococcal infection in children living in a low air exchange rate environment in developing 
countries [31]. There is a body of evidence for the association between the increasing global 
main temperature and increasing global mortality [32]. The heat-related risk of mortality for 
respiratory diseases needs to be addressed for relevant environmental measures focusing on 
the one health concept. Evidence of associations between outdoor heat and respiratory hos-
pitalizations has been reported in previous studies in developed countries, but data are lack-
ing on the harmful effects of climate change on health in developing regions, where global 
warming and progressive population aging are expected with the improved accessibility to 
ARVs and anti-tuberculosis treatments resulting in the reduction of the mortality linked to 
both killers. The role of sociodemographic components and low education as well as poor 
accessibility to healthcare in general are strong modifiers of treatment outcomes suggesting 
the relevance of their regular assessment as risk factors of respiratory illnesses. Along with the 
changing warming climate, the role of air pollution, evidenced in respiratory exacerbations 
of chronic diseases such as asthma, COPD, and cardiovascular diseases, following the inhala-
tion of ozone, SO
2
, CO
2
, CH
4,
 and particulate matters (PM10) (from increased forest fires, wild 
urbanization, desertification) with aerodynamic diameters <10 μm is reported in many stud-
ies [32, 33]. Greenhouse gas emissions generated by human activity are pointed as the main 
provider of the changing Earth’s climate through thermal stress, extreme weather events, 
and changing pattern of infectious diseases, suggesting the urgent need to develop strategies 
addressing human, animals, and plants health as a whole (one health concept). The climate 
change is expected to affect mainly vector-borne and water-borne infectious diseases, with a 
potential of increasing the range in case of nonadopting early preventive and warning mea-
sures [34]. Indirect effects of increased warming include shifts in vector-borne illness, increase 
in allergen concentration, loss of biodiversity, degradation of ecosystem, desertification, all 
with a negative impact on human health. Among realistic measures to reduce climate change-
related respiratory morbidity, green structures development has been considered. Whiitford 
et al. [35] and Burgess et al. [36] have reported the environmental benefits of green spaces on 
the stabilization of ecological system and the reduction of the risk of respiratory mortality. 
These authors showed that largest patch percentage of green structures reduces the mortality 
of pneumonia and lower respiratory diseases through the reduction of primary and secondary 
air pollutants; while their fragmentation has deleterious effect by increasing the temperature 
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and the air pollutants. Green spaces are shown to block secondary air pollutants (ozone and 
PM 2.5). Rationale management of green structures needs to be encouraged in the urbaniza-
tion policies among other preventive measures to improve respiratory health [37–39].
3. Community-acquired pneumonia (CAP): epidemiology, clinical 
feature, and treatment
3.1. CAP: epidemiology
Community-acquired pneumonia (CAP) is still the leading cause of death attributable to 
infectious diseases, and epidemiological data show that its attributable mortality rate remains 
static or is rising, while declining for cardiovascular diseases and many cancers in developed 
countries [40]. Mortality in European adults varies from country to country and based on 
the age, it ranges from 4.5 to 5 per 100,000 in turkey and Georgia to 30 to 35 per 100,000 in 
Portugal and UK [41]. Near a half of under-five deaths worldwide are due to preventable dis-
eases including pneumonia, diarrhea, and malaria with 2.2 million deaths in children under 5 
years in 2012, in Nigeria, Democratic Republic of Congo, India, Pakistan, and China [42]. The 
overall prevalence of CAP in Africa is unknown, due to the lack of standardized protocols 
and reporting. A study in Uganda reported Klebsiella pneumoniae as the prevalent pathogen 
in neonates and S. pneumoniae was the most common etiological agent in those aged between 
3 months and 5 years [43–45].
Outcome of pneumonia is still a health concern, mainly in developing countries, despite the 
development of new antibacterial agents. This phenomenon relays on the emerging antibiotic 
resistance of the pathogen on one hand and on host-related factors (impaired immunity, poor 
hygiene, age, malnutrition, comorbidities) on the other. Innovative approaches through better 
understanding of pathophysiology of the disease and environmental changes, early diagnosis 
techniques, multidisciplinary approach, and host-driven measures (behavior, accessibility to 
health facilities) need to be developed to improve the control of respiratory mortality.
Community-acquired pneumonias is the leading cause of death due to the infectious disease 
in both developed and developing world [22]. Developing countries are also the most affected 
due to many additional conditions such as poverty, low economic access to healthcare, lack 
of appropriate tools for early diagnosis, many socio-cultural barriers, and the unpreparedness 
against environmental changes. A study from Tanzania has identified the negative role of dif-
ficult diagnoses and comorbidities in the prognosis of CAP [46]. Children under 5 years and 
elderly are the most vulnerable population, and 30-day mortality has not been improved since 
the 1950s, despite the availability of new antibiotics [47]. CAP occurs in almost 1–10 per 1000 of 
the adult population each year and more commonly in extreme ages. According to the WHO 
European region report in 2010, lower respiratory tract infections ranked fifth in the global bur-
den disease study [30]. The same report identified infectious diseases, childhood illnesses, and 
maternal causes of death as accounting for 70% of the burden of diseases in sub-Saharan Africa, 
while representing <20% in all others countries. Even reduced compared to two decades ago, the 
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rate of mortality caused by diarrheal and low tract infection diseases remains high and the major 
cause of early deaths in the country. The big five, COPD, asthma, low respiratory tract infections, 
TB, and lung cancer are among the most common causes of severe illness death worldwide.
The lack of standardized protocols and regular statistic reports does not allow the assessment 
of accurate incidence rate of CAP across the sub-Saharan region. In Europe, this incidence rate 
in adults is between 1.07 and 1.2 per 1000 person year and 1.54 and 1.7 per 1000 population 
according to a report by Torres et al. [48]. Older age and underlying comorbidities including 
COPD, cardiovascular and liver diseases, diabetes, cancers as well as all causes of immuno-
suppression (steroids treatment, malnutrition, HIV-AIDS) affect the prognosis of the disease 
and this is highlighted by the CURB 65 criteria in use for assessing the severity of CAP. There 
is a regular increase in the incidence of CAP worldwide, may be associated to demographic 
changes, increasingly aging population, growing poverty, low accessibility to healthcare 
facilities, precarity and war displacements, smoking and alcohol consumption. It is more and 
more clear that air pollution and climate change play important roles in the rising morbidity 
and mortality related to respiratory diseases. The heat stress linked to the warming of the cli-
mate induces environmental changes allowing the emergence of new pathogens worldwide. 
The real involvement of these ecological modifications needs to be addressed.
3.2. Pathophysiology
Pneumonia could result from infectious pathogens including bacteria, viruses, fungi, and para-
sites, or from noninfectious agents, of physical or chemical nature (aspiration pneumonia, gas 
inhalation). The main route for bacterial contamination is bronchogenic dissemination following 
microaspiration of pharyngeal secretions. Hematogenous spread follows bloodstream invasion 
by pathogens; and infection could also spread from contiguous tissues. In the alveolar space, 
host local defenses through humoral or cellular-mediated immune responses or mechanical 
processes (mucociliary escalator, cough reflex) when overwhelmed, allow the infection onset. 
The inflammation in the lung structures results in the release of mediators and accumulation 
of an exudate impairing the local immune system. The thickening of the alveolocapillary mem-
brane alters the gas diffusion, inducing hypoxemia. The mismatch in the ventilation-perfusion 
ratio due to the reduced minute-ventilation increases the hypoxemia. Pneumococcal carriage in 
the posterior nasopharynx is a prerequisite for the development of pneumonia due to S. pneu-
moniae. Human to human transmission occurs through inhaled aerosols or close contact. The 
virulence of the pathogen is carried by factors allowing adhesion to the respiratory epithelium 
and released virulence factors such as pneumolysin and neuraminidase, which can damage the 
lung structures. The concentration of the pathogens is also a requirement for the onset of dis-
ease. Host immunity through humoral- and cell-mediated immunity is the main way of defense. 
Airway epithelium secretes also lactoferrin with the potential of deprecating the pathogen from 
iron, and then impairing the growth of the bacteria. Lysozyme and human defensins are along 
with cathelicidin-related antimicrobial peptides LL-37, also involved in the lysis of bacteria [49]. 
The classic evolution of acute pulmonary inflammatory response will turn in red hepatization, 
gray hepatization, and resolution. Main causes of CAP are S. pneumoniae, M. pneumoniae, H. 
influenzae, C. pneumoniae, Legionella sp., or respiratory virus with influenza A and B, respiratory 
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syncytial (RSV), rhinovirus, and parainfluenza as the most encountered. Fungal infection mainly 
affects immunocompromised patients and parasitic infections are mainly endemic [50]. Clinical 
syndrome of condensation and radiological alveolar syndrome occur in few days. Pathogens 
implicated in nosocomial infection include a larger panel with methicillin-resistant staphylococ-
cus aureus (MRSA), Enterobacteriaceae, and different types with a potential of resistance and 
difficult to treat infections.
3.3. Diagnosis of CAP
Patient with CAP mainly complaints of cough, fever, shivers, pleuritic chest pain of abrupt 
onset. Dyspnea may occur when the involved pulmonary sector is large. Sputum production 
is not rare, of purulent aspect or blood stained. Physical examination may reveal a condensa-
tion syndrome with focal crackles. It is of great importance to consider also extrathoracic signs 
(mouth, nose, ear).
History should be extended to demographic and behavioral considerations (age, gender, style 
and site of living) and comorbidities. CRB65, which is a clinical score for assessment of CAP 
is recommended in many guidelines. It includes data about confusion, respiratory rate, blood 
pressure, and age ≥ 65 years. A CRB65n score of 0 seems a patient at low risk of death and not 
normally requiring hospitalization.
Additional investigations are required to guide the diagnosis setting, such as inflammatory 
markers (leukocytosis and differential counts, ESR, CRP) and etiological identification of 
pathogens through conventional microbiological analyses of samples (sputum, nasotracheal 
aspirates, bronchoalveolar lavage), the latter could be positive in only 15% of cases. The quality 
of the specimen to be examined by gram stain is a prerequisite, and the sputum should contain 
more than 10–25 polymorphonuclear cells by microscopic screening to be suitable. Culture-
based techniques are widely used for the diagnosis of pneumonia. That is the case of blood, 
sputum cultures, or endotracheal aspirates, which can allow pathogen identification and anti-
biotic sensitivity tests. Urinary antigen tests are helpful for S. pneumoniae and L. pneumophila. 
Molecular diagnosis tools are currently more and more used for diagnosis of infectious dis-
eases. CRP, an acute-phase protein during acute inflammation has not proven to be accurate 
in differential diagnosis between bacterial or viral infections; it is nevertheless an indicator of 
response to the treatment. Other biomarkers are being developed, such as procalcitonin, a pro-
hormone elevated in response to bacterial infections. Studies using this biomarker have not 
provided sufficient probes for large clinical use [51]. Otherwise, both biomarkers are useful in 
the assessment of response to treatment and suitability of the antibiotic prescribed.
Serological tests find applicability in the diagnosis of pneumonia due to atypical pathogens 
such as Chlamydia, Mycoplasma, and viral infections, not easy to identify by current culture-
based techniques.
Molecular techniques are now developed ensuring an early diagnosis and sensitivity tests 
for resistance to treatment. Dried blood spots have been used for bacterial identification and 
have proven to be a useful and easily accessible tool for molecular diagnosis in poor resources 
countries [46]. Urinary antigen tests are available for S. pneumoniae and L. pneumophila. 
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Bronchoscopic aspirations are more relevant than sputum samples culture to minimize the 
likelihood of commensal flora.
Chest radiograph demonstrating a peripheral airspace consolidation pattern is relevant in the 
diagnosis of pneumonia. Lung shadowing of lobar pattern associated to air bronchogram is 
common, while centrilobular and peribronchiolar opacity are defining the bronchopneumonia 
pattern. The lower lobes are most commonly affected. Recent literature illustrates the relevance 
of lung ultrasound in the diagnosis of CAP. A multicenter study in 14 European centers has 
shown a sensitivity of 93.4% and a specificity of 97.7% in the confirmation of the diagnosis [52].
The differential diagnosis should consider all illness expressed with dyspnea such as pulmo-
nary embolism, COPD exacerbations, bronchiectasis, exacerbation of fibrosis, or with cough 
and associated fever such as acute bronchitis.
3.4. Complications of CAP and prevention
CAP mortality remains high despite the development of new antibiotics and new tools for 
early-onset diagnosis. Main complications are sepsis and respiratory failure, but about 50% of 
CAP mortality in the first month is due to comorbidities [53]. Respiratory infections through 
hypoxemia and oxidative stress are a potential determinant of cardiovascular adverse events. 
The underlying atherosclerosis as shown by the increased rate of inflammatory biomark-
ers (fibrinogen, CRP, cytokines) in infectious status may impact on prothrombotic vascular 
conditions and subsequent cardiovascular ischemic diseases [54, 55]. The prognosis of acute 
myocardial infarction, cardiac arrhythmias, and heart failure is often worsened by respiratory 
infections according to few previous studies [55–57].
CAP is not simply a local but systemic inflammatory response as expressed by the measur-
able increase in serum biomarkers such as IL-6, IL-8, and TNF-alpha. To improve patients’ 
outcomes, preventive measures are strongly recommended such as smoking cessation inter-
ventions and accurate screening of comorbidities. About a half of CAP mortality within the 
first month is due to the comorbidities such as cardiovascular complications, cancer, chronic 
lower respiratory diseases renal failure, and infections, mainly involving the elderly [58, 59]. 
Cardiovascular mortality contributes for almost 30% of deaths after CAP; that is the case of 
myocardial infarction in a multicenter study by Lichtman et al. reporting a 7.2% of CAP in 
patients admitted to the hospital with an acute myocardial infarction [60]. Cardiac arrhyth-
mias are also observed sometimes induced by the use of macrolides alone or in combination 
therapy [61]. Respiratory infections were more frequent (19 vs. 6%) in a comparison study of 
stroke patients and control [62], suggesting the comorbidity of this condition.
Empyema is a harmful complication of pneumonia occurring mostly in more vulnerable sub-
jects (comorbidities, immune disorders).
Preventive measures through behavioral changes such as smoking cessation and vaccination 
in vulnerable populations such as drepanocytosis patients, COPD, renal insufficiency patients 
with influenza, and pneumococcal vaccines need to be largely implemented to reduce the 
mortality rate.
Pneumonia: A Challenging Health Concern with the Climate Change
http://dx.doi.org/10.5772/intechopen.71609
43
3.5. Treatment of CAP
Severity assessment is a prerequisite to an accurate decision for the place of care (ICU or 
not). Empirical antibiotic therapy is widely used in the treatment of CAP and should include 
pneumococcal coverage. The promptitude of the treatment (less than 8 h from diagnosis) 
has been shown to improve mortality rate. Few recommendations by the American Thoracic 
Society (ATS) emphasize the relevance of some conditions such as the severity of the pneu-
monia, the previous health status of the patient, the comorbidities, and a previous use of 
antibiotic therapy less than 3 months. The combination therapy or the monotherapy is regu-
larly questioned, but evidence shows the superiority of the combination therapy in severe 
patients [57, 63, 64]. The use of pneumonia severity index and CURB 65 will help to improve 
the outcomes of CAP, by a relevant orientation of the patients. In ambulatory patients with 
mild to moderate disease, monotherapy, and mainly by oral route is a common practice. The 
empirical choice is the class of β-lactamases (amoxicillin) or macrolides in case of allergy to 
the former. Fluoroquinolones in monotherapy, even recommended in some developed coun-
tries such as the North America should be discouraged in the settings where TB is a great 
concern, because of the influence of these drugs on the delay of TB diagnosis and the lack of 
alternative diagnosis tools for smear-negative tuberculosis. Macrolides and doxycycline are 
suitable when mycoplasma or chlamydia are the suspected etiologic agents. A previous his-
tory of antibiotic therapy in the latter 3 months guides the choice for a not yet used antibiotic 
by the patient. This is to minimize the emergence of resistance to antibiotics. In hospitalized 
patients, a part from taking care of the comorbidities, monotherapy using amoxicillin-cla-
vulanic acid may be a choice according to the severity of the illness; combination therapy of 
the latter with advanced macrolides (clarithromycin, azithromycin) is often recommended. 
In case of a risk of aspiration pneumonia (Dementia, Alzheimer, Diphtheria), the clindamy-
cin should be added. Patients admitted in ICU need combination therapy as first choice and 
G3-cephalosporins; or carbapenems are regularly prescribed. The emergence of resistance 
is nevertheless a threat in these critically ill subjects. Adjunctive therapies in hospitalized 
patients include oxygen suppliance if necessary, low doses corticosteroids in suspected 
adrenal insufficiency following the bacteremia phase may be added to improve outcomes. 
Nonsevere CAP could be treated ambulatory with a 7-day monotherapy with oral antibiotics. 
The use of pneumonia severity index and CURB 65 or serum biomarkers may improve the 
prognosis of the illness. Among the biomarkers, the procalcitonin has been assessed in the 
decision of initiation or discontinuation of antibiotic therapy in adults. The discontinuation 
may be applied if the PCT level after 3 days is lower than 0.25 ng/mL or as decreased by more 
than 80–90% relative to the initial value [65].
4. Conclusion
Pneumonia remains a global threat despite the development of newer antibiotics. Early 
diagnosis tools need to be widely available, including easily accessible molecular analyzes. 
The empirical antibiotic treatment should relay on site of care, severity index of the disease, 
comorbidities, cost effectiveness, but also on identifications of new risk factors challenging the 
outcomes of patients such as climate changes.
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